Jack Allen
Stock Analyst at Baird
(1.49)
# 3,429
Out of 5,182 analysts
44
Total ratings
40%
Success rate
-9.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $7 → $9 | $2.39 | +276.57% | 4 | Apr 14, 2026 | |
| ACLX Arcellx | Downgrades: Neutral | $106 → $115 | $115.05 | -0.04% | 6 | Feb 23, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $52 → $44 | $57.99 | -24.12% | 3 | Nov 11, 2025 | |
| VOR Vor Biopharma | Upgrades: Outperform | $20 → $64 | $16.59 | +285.77% | 5 | Oct 15, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $7 → $12 | $6.43 | +86.63% | 5 | Oct 2, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.39 | +187.77% | 2 | May 14, 2025 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $14.21 | +181.49% | 2 | Nov 15, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $14.95 | +20.40% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $8.94 | +1,914.55% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $0.34 | +2,276.71% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $31.45 | +167.09% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.71 | +192.40% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.42 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $4.13 | +117.92% | 1 | Oct 7, 2021 |
Allogene Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $7 → $9
Current: $2.39
Upside: +276.57%
Arcellx
Feb 23, 2026
Downgrades: Neutral
Price Target: $106 → $115
Current: $115.05
Upside: -0.04%
CRISPR Therapeutics AG
Nov 11, 2025
Maintains: Neutral
Price Target: $52 → $44
Current: $57.99
Upside: -24.12%
Vor Biopharma
Oct 15, 2025
Upgrades: Outperform
Price Target: $20 → $64
Current: $16.59
Upside: +285.77%
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7 → $12
Current: $6.43
Upside: +86.63%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.39
Upside: +187.77%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $14.21
Upside: +181.49%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $14.95
Upside: +20.40%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $8.94
Upside: +1,914.55%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $0.34
Upside: +2,276.71%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $31.45
Upside: +167.09%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.71
Upside: +192.40%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $4.42
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $4.13
Upside: +117.92%